Payer delays risk access to timely care for people w cancer. ASCO member Dr. Patt shares a powerful example of how #priorauthorization impedes care. It’s why we’re urgently asking lawmakers to #FixPriorAuth & protect pts w cancer. fal.cn/3wis3 #ASCOAdvocacy

Fighting Prostate Cancer With Exercise (Part 2): What Kind of Exercise? | Prostate Cancer Foundation pcf.org/c/fighting-pro…

NATALEE trial meets primary endpoint at interim analysis! Adjuvant Ribociclib (400mg) + AI improved iDFS compared to AI alone in patients with stage II, III ER+ breast cancer regardless of LN improvement. Novartis #breastcancer novartis.com/news/media-rel…

Excited to see these! The US Oncology Network Community Oncology Texas Oncology

For 30 years, we’ve expanded access to cutting-edge therapies and have conducted 700+ first-in-human trials. We could not have done this without our expert physicians, talented clinical teams, and everyone behind the scenes who live our mission to serve patients every day.

Ab#5015 #ASCO23 ASCO : In PANTHER Ph 2 trial: Rx with apalutamide + abiraterone showed promising efficacy in NHT naive Black pts in 1st line mCRPC #prostatecancer➡️rPFS, OS, PSA 50% response👇 Congrats Dan George and team for these clinically relevant data Andrew Armstrong

I’m proud to have the opportunity to work with this outstanding person and amazing doctor. Congratulations William K. Oh MD !

Spent a good evening thinking about #prostatecancer w Mark T. Fleming, M.D. Oliver Sartor @morr316 Mehmet Asim Bilen,MD Vadim Koshkin MD #AnaAparicio Przemysław Twardowski #RobDreicer Ben Gartrell, MD #DanGeynisman— haven’t seen some of these colleagues since before COVID!! ASCO #ASCO23

Proud and excited to have ⁦Ishwaria Subbiah, MD MS FASCO⁩ ⁦Vivek Subbiah, MD⁩ join our ⁦Sarah Cannon Docs⁩ team ! Already making an impact ⁦ASCO⁩

Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Tom Powles Robert Motzer MD Hans Hammers

Impressive presentation by Thomas Hutson, DO, PharmD, PhD FACP regarding updated CLEAR data Len + Pembro - it works. Kidney/Bladder Session chaired by manojkumar. Sarah Cannon Docs showing the science collaboration begins with us! The GU committee allstars are very proud:Benjamin Garmezy Mike Lattanzi Jeff Yorio, MD.

David Braun discusses #KEYNOTE426 & #CLEAR study abstracts 1] Data reinforces front line practices of IO/TKI but what about favorable risk? 2]CONTACT03 showed immediate rechallenge did not improve OS but does not answer the question of long term rechallenge with IO ASCO #ASCO23

Powerhouse brainy David Braun Yale Cancer Center w/ such excellent graphics & insightful discussion on 1st line & refractory #kidneycancer. Decision tree is spot on!! And patient perspectives KCCure are important for shared decision making. Thanks for plug on #PDIGREE! ASCO #ASCO23

FGFR important in UC. Should be tested in all. Great presentation - as always by Dr Siefer-Radtke.

Dr. Danso moderated this afternoon’s #ASCO23 metastatic breast cancer session where Erika Hamilton, MD delivered exciting data on a phase 2 HER3-Dxd study Daiichi Sankyo #VirginiaOncologyAssociates

Phase 3 #THOR study: Results of erdafitinib vs chemotherapy in patients with advanced or #mUC with select fibroblast growth factor receptor alterations. Presentation by Yohann Loriot Gustave Roussy. #ASCO23 written coverage by Zach Klaassen > bit.ly/3qtf3bx ASCO

Standing next to the GU Allstars ⁦⁩at #ASCO23 with ⁦Thomas Hutson, DO, PharmD, PhD FACP⁩ ⁦⁦manojkumar⁩ . They did a wonderful job!So proud of them! The Science of Collaboration Begins With Us ⁦Sarah Cannon Docs⁩ ⁦Skip Burris, MD⁩ ⁦David R. Spigel, MD, FASCO⁩ ⁦

The MSK Genitourinary Oncology Service is seeking a GU medical oncologist focused on prostate cancer clinical and translational research at the assistant professor level. Join a great team! @morr316 Aaron Mitchell Andy Laccetti MD, MS Dana Rathkopf MSK Department of Medicine tinyurl.com/3x6x9jyn

3rd year oncology fellows: We're hiring for our Eugene practice. Join a top 10% MGMA practice with incredible clinical research and sub-specialization opportunities. 4d clinic schedule with pretty light hospital responsibilities. Group includes rad onc / Gyn onc and 25 docs!

Manojkumar Bupathi, MD, MS, highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and more. #oncology #pcsm onclive.com/view/combinati…